SUMMIT UK - Small Cell Lung Cancer Outcomes Among Patients in the UK
Research type
Research Study
Full title
SUMMIT UK – Small Cell Lung Cancer Outcomes Among Patients in the UK
IRAS ID
245528
Contact name
Sanjay Popat
Contact email
Sponsor organisation
AbbVie Ltd UK
Clinicaltrials.gov Identifier
NA, NA
Duration of Study in the UK
0 years, 6 months, 30 days
Research summary
This is a retrospective, longitudinal cohort study conducted in patients with small cell lung cancer (SCLC) in the UK. SCLC is a less common, more aggressive subtype of lung cancer which usually spreads faster than non-small-cell lung cancer. Most patients are diagnosed with the advanced stage of the disease hence the prognosis is poor.
The study will use pseudonymised patient data extracted from medical records by the direct care team at each participating centre and provided to the research team for analysis. The research team will have no access to any identifiable records for the study.
The study will be conducted in 5-6 hospitals in the UK. Approximately 200 patients with SCLC will be included in the study across all participating centres.
REC name
HSC REC B
REC reference
18/NI/0119
Date of REC Opinion
19 Jun 2018
REC opinion
Favourable Opinion